Trial · NCT04974216
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Response Rate (ORR) by local assessment | 3 months (3 cycles of 28 days) | LOCAL ASSESSMENT : Complete Metabolic Response + Partial Metabolic Response based according to Lugano Response Criteria |
| Secondary | Number of Serious Adverse Events (SAE) of patients treated with lenalidomide and tafasitamab | 13 months | |
| Secondary | Number of SAE of patients who switched to RminiCHOP | 7 months | |
| Secondary | Progression free survival (PFS) | 2 years | |
| Secondary | Overall survival (OS) | 2 years | |
| Secondary | Overall Response Rate (ORR) by central assessment | 3 months (3 cycles of 28 days) | CENTRAL ASSESSMENT : Complete Metabolic Response + Partial Metabolic Response based according to Lugano Response Criteria |
| Secondary | Complete Metabolic Response (CMR) by local assessment | 3 months (3 cycles of 28 days) | LOCAL ASSESSMENT |
| Secondary | Complete Metabolic Response (CMR) by central assessment | 3 months (3 cycles of 28 days) | CENTRAL ASSESSMENT |
| Secondary | Complete Metabolic Response (CMR) by local assessment | 6 months (6 cycles of 28 days) | LOCAL ASSESSMENT |
| Secondary | Complete Metabolic Response (CMR) by central assessment | 6 months (6 cycles of 28 days) | CENTRAL ASSESSMENT |
| Secondary | Complete Metabolic Response (CMR) by local assessment | 12 months (12 cycles of 28 days = end of treatment) | LOCAL ASSESSMENT |
| Secondary | Complete Metabolic Response (CMR) by central assessment | 12 months (12 cycles of 28 days = end of treatment) | CENTRAL ASSESSMENT |
| Secondary | Overall Response Rate (ORR) by local assessment | 6 months (6 cycles of 28 days) | LOCAL ASSESSMENT : Complete Metabolic Response + Partial Metabolic Response based according to Lugano Response Criteria |
| Secondary | Overall Response Rate (ORR) by central assessment | 6 months (6 cycles of 28 days) | CENTRAL ASSESSMENT : Complete Metabolic Response + Partial Metabolic Response based according to Lugano Response Criteria |
| Secondary | Overall Response Rate (ORR) by local assessment | 12 months (12 cycles of 28 days = end of treatment) | LOCAL ASSESSMENT : Complete Metabolic Response + Partial Metabolic Response based according to Lugano Response Criteria |
| Secondary | Overall Response Rate (ORR) by central assessment | 12 months (12 cycles of 28 days = end of treatment) | CENTRAL ASSESSMENT : Complete Metabolic Response + Partial Metabolic Response based according to Lugano Response Criteria |
| Secondary | Progression free survival (PFS) of patients who switched to RminiCHOP | 3 years | |
| Secondary | Overall survival (OS) of patients who switched to RminiCHOP | 3 years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04974216/registered